Physician profile
Timothy E Jessen
NPI 1831165034
$3,209.56
in general payments reported to CMS, 2019-2025
19 companies · $545 in 2025
The $545 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $292 · 2021: $526 · 2022: $367 · 2023: $448 · 2024: $477 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,371.53 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $941.27 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $521.00 | 2019-2024 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $513.59 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $403.74 | 2019-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $181.90 | 2020-2025 | |
| Amgen INC. | $151.90 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $70.56 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $65.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.02 | 2021-2025 | Takhzyro, Cuvitru |
| Pfizer INC. | $57.63 | 2019-2023 | |
| Genentech USA, INC. | $45.01 | 2025 | Xolair |
| Alk-Abello, INC | $42.77 | 2019 | |
| Mylan Specialty L.P. | $33.12 | 2019-2023 | Yupelri |
| Csl Behring | $28.22 | 2021-2025 | Haegarda |
| Merck Sharp & Dohme LLC | $24.67 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $23.43 | 2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.62 | 2021 | |
| Astellas Pharma US INC | $14.42 | 2024 | Veozah |
| Optinose US, INC. | $11.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Jessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.